In a report released on May 5, Andrew Berens from SVB Securities reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $3.48.
According to TipRanks, Berens is a 2-star analyst with an average return of 0.0% and a 46.33% success rate. Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Incyte, and Seagen.
Currently, the analyst consensus on Compass Therapeutics is a Strong Buy with an average price target of $9.67, implying a 177.87% upside from current levels. In a report released on May 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Compass Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.84 million. In comparison, last year the company had a GAAP net loss of $7.16 million
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.
Read More on CMPX:
- CMPX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
- Compass Therapeutics removed from Best Ideas List at Wedbush
- Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
- Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
